Access to Liver Transplantation and Patient Survival among Asian Populations: Pre-Share 35 vs Post-Share 35

Y. Zhang

Department of Biostatistics, School of Public Health, University of Texas Health Science Center, Houston, TX, USA

ABSTRACT

Background: Studies addressing ethnic disparities and trends in liver transplantation for Asian population are scant.

Objective: To examine the impact of Share 35 policy on Asian patients’ access to liver transplantation and outcomes since its implementation in June 2013.

Methods: A total of 11,910 adult white and Asian patients who were registered for deceased donor liver transplantation between 2012 and 2015, was identified from the United Network for Organ Sharing database. Logistic regression and proportional hazard models with adjustment for demographic, clinical and geographic factors were used to model the access to liver transplantation and patient survival. Stratification on pre- and post-Share 35 periods was performed to compare the first 18 months of Share 35 policy to an equivalent period.

Results: Comparison of the pre- and post-Share 35 periods showed a significant decrease in time on waiting list and higher proportions of patients receiving liver transplantation for Asian patients. Asians shared similar transplant rates as whites (OR: 1.15, 95% CI: 0.80–1.67) but experienced significantly longer waiting time (HR: 0.56, 95% CI: 0.34–0.92) before they received liver transplantation after Share 35 policy took effect. No significant post-transplantation survival difference was observed between Asians and whites at the 18-month outcome.

Conclusion: Although benefited from the Share 35 policy, Asian patients are still at greater risk of disparities in access to liver transplantation.

KEYWORDS: Asian continental ancestry group; Health status disparities; Liver transplantation; Share 35 policy; United Network for Organ Sharing

INTRODUCTION

Based on the US Census Bureau Population Projections, it is estimated that minority populations would grow by 2% per year over the next two decades. Asian population will make up approximately 11.7% of the US population by 2060 [1]. Most of the studies addressing ethnic disparities and trends in liver transplantation have focused on African-Americans and Hispanics and the information for Asian population is scant [2-5]. One preliminary study using national cancer surveillance data from 1998–2002 found that white patients were 2.56 times more likely to receive a liver transplantation than Asian and Pacific Islanders with hepatocellular carcinoma (HCC) in the pre-Model for End-Stage Liver Disease (MELD) era, but not in the post-MELD era from 2003–2005 [6]. Another study on the United Network for Organ Sharing (UNOS) database for all adult Asian liver transplantation recipients from 1998–2007 indicates that Asian ethnicity has a significant survival advantage in comparison to non-Asians [7].

On June 18, 2013, the Share 35 policy was implemented by the UNOS, which dramatically changed the allocation of donor livers. It mandates that regional sharing of livers for patients with a MELD score of ≥35 is prioritized over local sharing to patients with
the MELD score of <35. The intention of the policy was to reduce the waiting list mortality. Recent preliminary analyses have reported decreased mortality rates under Share 35 policy, but they did not observe any significant difference in the post-transplantation survival [6-9]. However, no study has ever investigated among Asian populations.

The objective of this study was therefore to assess the access to liver transplantation and transplantation outcomes among Asian populations under the Share 35 policy using the recent UNOS waiting list and liver database comparing the first 18 months of Share 35 policy to an equivalent period before, while accounting for geographical and other factors.

PATIENTS AND METHODS

Data Source
UNOS is a private, non-profit organization that manages the nation’s organ transplant system under contract with the federal government [10]. Detailed descriptions of the UNOS registry have been published elsewhere [11]. Briefly, data are collected by each transplant center and transmitted to UNOS. The registry records and documents any changes in standard demographic, clinical, and laboratory information available at the time of listing, during transplantation, and post-transplantation, as well as information on the donors. The Standard Transplant Analysis and Research (STAR) file of the UNOS database contains one record per transplantation event.

The committee for the Protection of Human Subjects at the University of Texas Health Science Center at Houston approved this study.

Study Population
A total of 15,789 candidates with end-stage liver disease (ESLD), 18 years of age and older, with an initial data of registration for deceased donor liver transplantation between January 1, 2012 and March 31, 2015, was identified from the STAR wait list and liver file of the UNOS database. Only candidates with race/ethnicity defined as non-Hispanic white and Asian were selected (n=11,919). Candidates were then excluded for the following reasons: missing body mass index (BMI) (n=3), missing diagnosis (n=5), and unknown MELD score at listing (n=1). After all exclusions, a total of 11,910 patients was available for analysis.

Study Variables
The exposure variable of primary interest was race and ethnicity as reported in UNOS records, classified as non-Hispanic white (severing as the reference group) and Asian. Other patient demographic and clinical characteristics included age at listing, sex, BMI, diagnosis, MELD score at listing, time on waiting list, waiting list outcomes, presence of HCC, presence of hepatitis C virus (HCV), presence of hepatitis B virus (HBV), organ location, and history of diabetes.

The primary outcomes for all waiting list candidates included (1) the receipt of liver transplantation, and (2) the total time on the waiting list. Follow-up began for patients when they were initially added to the waiting list. They were then followed until the earliest of liver transplantation, death, the granting of a MELD exception score, or the end of the study. Patients received a liver transplant, alive, or lost to follow-up were censored at the date of transplantation or the last follow-up.

Among those who received liver transplant, another primary outcome was post-transplantation patient survival. Patient survival in years was calculated from the date of liver transplantation to the date of death or the date of the last follow-up. Recipients alive or lost to follow-up were censored at the date of last follow-up.

Statistical Analysis
χ² and Student’s t tests were used to compare the baseline demographics and clinical characteristics between the two racial groups as well as between pre-Share 35 and post-Share 35 periods. To incorporate the impact of geography and transplant center, marginal logistic regression models and Cox proportional hazard models were used to model the effects of Asian race on the receipt of liver transplantation, the
total waiting time on the list, and post-transplantation survival. All other potential risk factors were included in the models. Stratifications between pre-Share 35 and post-Share 35 periods were also performed. All statistical analyses were performed with SAS ver 9.4 (SAS Institute Inc, Cary, NC, USA). A p value <0.05 was considered statistically significant.

RESULTS

The baseline demographic and clinical characteristics of the 11,910 patients registered on waiting list are presented in Table 1. Compared to the pre-Share 35 cohort, Asian and white subgroups in the post-Share 35 cohort were similar in terms of age at listing, sex, HCV status, HBV status, and history of diabetes. The median time on waiting list decreased significantly from 126 days to 53.5 days for Asians and from 92 days to 53 days for whites. When it came to waiting list outcomes, both Asians (increased from 82.4% to 87.2%) and whites (increased from 81.2% to 85.2%) had higher proportions of patients receiving liver transplantation, while lower proportions of patients still waiting on the list or being too sick to receive transplantation. There were significantly more Asian patients with higher BMI, MELD score >35 registered on the waiting list, negative HCC, and more regional organs after the implementation of the Share 35 policy.

Table 2 shows the risk-adjusted odds ratios for liver transplantation rates among patients registered on waiting list for both pre- and post-Share 35 periods. Asian candidates shared similar likelihood of receiving liver transplantation as compared to white candidates, both in the pre-Share 35 era (OR: 1.04, 95% CI: 0.77–1.41) and post-Share 35 era (OR: 1.15, 95% CI: 0.80–1.67).

The Cox proportional hazard regression results of the waiting time before the access to liver transplantation for both pre- and post-Share 35 periods are presented in Table 3. Asian patients had to wait approximately 50% longer on the waiting list before receiving a liver transplant compared to white patients (HR: 0.56, 95% CI: 0.34–0.92) after implementation of the Share 35 policy.

We further investigated the post-transplantation survival for patients who were removed from waiting list and received a liver transplant. The Cox proportional hazard regression results are presented in Table 4. No statistically significant difference in patients’ survival between Asian and white patients was observed either in pre-Share 35 (HR: 0.82, 95% CI: 0.58–1.16) or in post-Share 35 era (HR: 0.92, 95% CI: 0.59–1.44) at the 18 month outcome.

DISCUSSION

Overall, the study observed significant decreased time on waiting list and higher proportion of patients receiving a liver transplant for both Asians and whites after the Share 35 policy. Although benefited from the new policy, Asian patients had similar transplantation and survival rates as their white counterparts, and still experienced 50% longer waiting time before the receipt of a liver transplant. To the best of our knowledge, this study was the first study to explore the access to liver transplantation and patient survival for Asian patients with ESLD after the Share 35 policy implemented in June 2013.

Apparently, for both Asian and white patients added to the UNOS waiting list, the Share 35 policy significantly shortened their waiting time on list, increased the percentages of regional organs, and improved their waiting list outcomes, as measured by death prior to transplantation or removal from the waiting list due to being too sick for transplantation. An important finding in this study was the lack of disparities in transplantation rates between Asians and whites after accounting for other demographic, clinical and geographic characteristics. This finding was comparable to preliminary results of recent studies after Share 35 policy took effect [4, 7-9]. Therefore, the implementation of Share 35 policy, with its emphasis on reducing mortality on wait-
ing list, though did not lead to improved access to a liver transplant for Asian patients so far, eliminated the previously observed disparities in waiting list. However, compared to white candidates, Asians still need to wait almost 50% more before they received a liver

Table 1: Baseline demographic and clinical characteristics of waiting list candidates in the entire cohort by race: pre-Share 35 vs post-Share 35 periods, 2012–2015

| Variable                                      | Pre-Share 35, (n=6112) | Post-Share 35, (n=5798) |
|-----------------------------------------------|------------------------|-------------------------|
|                                               | White, (n=5772)        | Asian (n=340)           | White, (n=5486) | Asian (n=312) |
| Mean±SD age at listing (yrs)                  | 55.7±9.9               | 55.1±11.5               | 55.6±10.5       | 54.8±10.7     |
| Sex, n (%)                                    |                        |                         |                |
| Male                                          | 3913 (67.8)            | 225 (66.2)              | 3694 (67.3)     | 203 (65.1)    |
| Female                                        | 1859 (32.2)            | 115 (33.8)              | 1792 (32.7)     | 109 (34.9)    |
| Mean±SD BMI (kg/m²)                           | 28.5±5.6               | 24.9±4.1                | 28.6±5.9        | 25.3±4.9      |
| Median (IQR) time on waiting list (d)         | 92 (21–246)            | 126 (26–350)            | 53 (11–146)     | 53.5 (7–188)  |
| Waiting list outcomes, n (%)                  |                        |                         |                |
| Transplanted                                  | 4685 (81.2)            | 280 (82.4)              | 4673 (85.2)     | 272 (87.2)    |
| Still waiting                                 | 235 (4.1)              | 21 (6.2)                | 166 (3.0)       | 17 (5.5)      |
| Temporarily too sick                          | 633 (11.0)             | 28 (8.2)                | 489 (8.9)       | 14 (4.5)      |
| Insurance issues                              | 89 (1.5)               | 1 (0.3)                 | 70 (1.3)        | 3 (1.0)       |
| Medical non-compliance                        | 53 (0.9)               | 1 (0.3)                 | 22 (0.4)        | —             |
| Candidate withdrawn                           | 73 (1.3)               | 9 (2.7)                 | 63 (1.2)        | 5 (1.6)       |
| Candidate cannot be contacted                  | 4 (0.1)                | —                       | 3 (0.1)         | 1 (0.3)       |
| MELD at listing, n (%)                        |                        |                         |                |
| <35                                           | 5288 (91.6)            | 307 (90.3)              | 4739 (86.4)     | 244 (78.2)    |
| ≥35                                           | 484 (8.4)              | 33 (9.7)                | 747 (13.6)      | 68 (21.8)     |
| Presence of HCC, n (%)                        |                        |                         |                |
| No                                            | 4358 (75.5)            | 191 (56.2)              | 4340 (79.1)     | 208 (66.7)    |
| Yes                                           | 1414 (24.5)            | 149 (43.8)              | 1146 (20.9)     | 104 (33.3)    |
| Presence of HCV, n (%)                        |                        |                         |                |
| No                                            | 3263 (56.5)            | 245 (72.1)              | 3350 (61.1)     | 234 (75.0)    |
| Yes                                           | 2344 (40.6)            | 87 (25.6)               | 1931 (35.2)     | 68 (21.8)     |
| Unknown                                       | 165 (2.9)              | 8 (2.4)                 | 205 (3.7)       | 10 (3.2)      |
| Presence of HBV, n (%)                        |                        |                         |                |
| No                                            | 4511 (78.2)            | 136 (40.0)              | 4437 (80.9)     | 117 (37.5)    |
| Yes                                           | 935 (16.2)             | 186 (54.7)              | 801 (14.6)      | 182 (58.3)    |
| Unknown                                       | 326 (5.6)              | 18 (5.3)                | 248 (4.5)       | 13 (4.2)      |
| Organ location, n (%)                         |                        |                         |                |
| Local                                         | 4376 (75.8)            | 252 (74.1)              | 3609 (6.8)      | 182 (58.3)    |
| Regional                                      | 1222 (21.2)            | 77 (22.7)               | 1654 (30.2)     | 121 (38.8)    |
| National                                      | 174 (3.0)              | 11 (3.2)                | 223 (4.1)       | 9 (2.9)       |
| History of diabetes, n (%)                    |                        |                         |                |
| No                                            | 4307 (74.6)            | 234 (68.8)              | 4084 (74.4)     | 237 (76.0)    |
| Yes                                           | 1437 (24.9)            | 106 (31.2)              | 1394 (25.4)     | 75 (24.0)     |
| Unknown                                       | 28 (0.5)               | —                       | 8 (0.2)         | —             |
transplant, regardless of Share 35 policy. Delayed in the access to liver transplantation was found likely to result in higher MELD scores, more advanced disease, greater disease-related morbidity, impaired access to quality pre-transplantation care, and may even be associated with worse post-transplantation outcomes [5, 12, 13]. Possible reasons behind the long waiting time included the partly shortage of eligible liver donors in the donor pool where the majority of donors are white [14], as numerous studies have already highlighted the adverse impact of donor and recipient race mismatch on post-transplantation outcomes [15, 16].

Although we studied different populations and time periods, our results were comparable to those preliminary analyses that showed there are still no significant difference in the post-transplantation patients’ survival between Asian and white patients when considering transplant center effects and other factors at 18 month outcome under the new policy. Continued investigations with longer follow-up would be necessary to assess the long-term impact of donor and recipient race mismatch on post-transplantation outcomes [15, 16].

Moreover, an interesting finding was that the average BMI among Asian patients in this study demonstrated an increasing trend in the post-Share 35 era, though it was significantly lower than the white cohort. This is especially important for Asian populations since they had greater rates of central obesity and visceral deposition of fat and therefore, were at greater risk of metabolic syndrome and non-alcoholic fatty liver disease (NAFLD) compared to other ethnic groups with similar BMI [20, 21]. This may further contribute to increased risk of developing nonalcoholic steatohepatitis (NASH) and may result in an increasing number of patients impacting the liver transplantation waiting list [22].

This study has limitations inherent to the retrospective nature and lack of systematic data

| Ethnicity | Pre-Share 35, (n=4965) | Post-Share 35, (n=5798) |
|-----------|------------------------|------------------------|
| White     | 1                      | 1                      |
| Asian     | 1.04 (0.77–1.41)       | 1.15 (0.80–1.67)       |

Table 3: Cox proportional hazard regression analysis results for the waiting time before liver transplantation among patients registered on waiting list: pre-Share 35 vs post-Share 35 periods, 2012–2015. Values are HRs (95% CI) adjusted for age, sex, BMI, diagnosis, MELD score at listing, presence of HCC, presence of HCV, presence of HBV, organ location, and history of diabetes.

| Ethnicity | Pre-Share 35, (n=6112) | Post-Share 35, (n=5798) |
|-----------|------------------------|------------------------|
| White     | 1                      | 1                      |
| Asian     | 0.65 (0.41–1.03)       | 0.56 (0.34–0.92)       |

Table 4: Cox proportional hazard regression analysis results of patient survival among patients who received a liver transplant: pre-Share 35 vs post-Share 35 periods, 2012–2015. Values are HRs (95% CI) adjusted for age, sex, BMI, diagnosis, MELD score at listing, presence of HCC, presence of HCV, presence of HBV, organ location, and history of diabetes.

| Ethnicity | Pre-Share 35, (n=4965) | Post-Share 35, (n=4945) |
|-----------|------------------------|------------------------|
| White     | 1                      | 1                      |
| Asian     | 0.82 (0.58–1.16)       | 0.92 (0.59–1.44)       |
collection of the UNOS database. Racial and ethnicity data were self-reported, which was prone to misclassification bias. Second, the statistical models were limited by variables in the UNOS database. Socioeconomic factors such as education, median household income, and health insurance status were not collected; these have been considered to be conceptually linked to a patient’s choice of a transplant center as well as the access to liver transplantation [4, 23–26]. In addition, genetic variations that contributed to lower survival rates in the post-transplantation setting were not available, either. Recipients with CYP3A5 polymorphism, which occurs in 10%–40% of whites and 33% of Asians in the general population, require a higher dose of tacrolimus to achieve target trough levels for immunosuppressive therapies [27]. However, due to the size of the database, the analysis of the UNOS is so far the most possible and comprehensive analysis today.

In conclusion, this study was the first and largest to date reporting on the trends and outcomes of liver transplantation among Asian ethnicity residing in the USA under the Share 35 policy, and it adds to the existing knowledge for other ethnic groups. We would agree that the liver allocation system is getting fairer than decades ago but balancing the access to the scarce medical resources remains a challenge to the entire transplant community including physicians, surgeons, and policy makers. Future research studies with long-term follow-up are recommended to continuously evaluate the effectiveness of the new policy.

ACKNOWLEDGMENTS

The author acknowledged the efforts of the United Network for Organ Sharing (UNOS) in the creation of this database. The interpretation and reporting of these data are the sole responsibilities of the author.

CONFLICTS OF INTEREST: None declared.

FINANCIAL SUPPORT: No financial support was provided for the completion of this study.

REFERENCES

1. Colby SL, Ortmann JM. Projections of the size and composition of the U.S. population: 2014 to 2060. Current Population Reports 2015; 25-1143.
2. Robbins AS, Daily MF, Aoki CA, et al. Decreasing disparity in liver transplantation among white and Asian patients with hepatocellular carcinoma, California, 1998-2005. Cancer 2008;113:2173-9.
3. Kemmer NM, Neff GW. Liver transplantation trends and survival in the Asian population. Transplantation 2009;88:392-4. doi: 10.1097/TP.0b013e3181ae68dc.
4. Mathur AK, Schaube DE, Gong Q, et al. Racial and ethnic disparities in access to liver transplantation. Liver Transpl 2010;16:1033-40.
5. Kemmer N. Ethnic disparities in liver transplantation. Gastroenterol Hepatol 2011;7:302-7.
6. Reid AE, Resnick M, Chang Y, et al. Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transpl 2004;10:834-41.
7. Massie AB, Chow EKH, Wickliffe CE, et al. Early changes in liver distribution following implementation of Share 35. Am J Transplant 2015;15:659-67.
8. Annapamalai A, Ayoub W, Sundaram V, Klein A. First look: one year since inception of regional Share 35 policy. Transplant Proc 2015;47:1585-90.
9. Gentry SE, Chow EK, Whickliffe CE, et al. Impact of broader sharing on the transport time for deceased donor livers. Liver Transpl 2014;20:1237-43.
10. United Network for Organ Sharing, 2016. Available from www.unos.org/about/index.php. (Accessed June 10, 2016)
11. Harper AM, Baker AS. The UNOS OPTN waiting list: 1988-1995. Clin Transpl 1995;69-84.
12. Moylan CA, Brady CW, Johnson JL, et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008;300:2371-8.
13. Mathur AK, Sonnenday CJ, Merion RM. Race and ethnicity in access to and outcomes of liver transplantation: a critical literature review. Am J Transplant 2009;9:2662-8.
14. U.S. Department of Health and Human Services. 2012 National survey of organ donation attitudes and behaviors. Available from www.organdonor.gov/dtcp/nationalsurveyorgandonation.pdf. (Accessed June 10, 2016)
15. Layden JE, Cotler SJ, Grim SA, et al. The impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation 2012;93:444-9.
16. Norvell JP, Levitsky J. Donor and recipient effects
on graft and patient survival. Clinical Liver Disease 2013;2:152-5.

17. Roberts JP, Dykstra DM, Goodrich NP, et al. Geographic differences in event rates by Model for End-Stage Liver Disease score. Am J Transplant 2006;6:2470-5.

18. Trotter JF, Osgood MJ. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA 2004;291:1871-4.

19. Zorzi D, Rastellini C, Freeman DH, et al. Increase in mortality rate of liver transplant candidates residing in specific geographic areas: analysis of UNOS data. Am J Transplant 2012;12:2188-97.

20. Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. World J Hepatol 2014;6:263-73.

21. Farrell GC, Wong VM, Chitturi S. NAFLD in Asia as common and important as in the West. Nat Rev Gastroenterol Hepatol 2013;10:307-18.

22. Charlton MR, Burns JM, Pederson RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-53.

23. Bryce CL, Angus DC, Arnold RM, et al. Sociodemographic differences in early access to liver transplantation services. Am J Transplant 2009;9:2092-101.

24. Ananthakrishnan AN, Saeian K. Racial differences in liver transplantation outcomes in the MELD era. Am J Gastroenterol 2008;103:901-10.

25. Yoo HY, Thuluvath PJ. Outcome of liver transplantation in adult recipients: influence of neighborhood income, education, and insurance. Liver Transpl 2004;10:235-43.

26. Thammana RV, Knechtle SJ, Romero R, et al. Racial and socioeconomic disparities in pediatric and young adult liver transplant outcomes. Liver Transpl 2014;20:100-15.

27. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-94.